Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2018

Prediction of recurrence and survival using PET SUV Max in patients with resected non-small cell lung cancer (#335)

Wei-Sen Lam 1 , Claire Savage 2 , Terry Hung 3 , Michelle McMullen 2
  1. Medical Oncology, Fiona Stanley Hospital, Murdoch, WA, AUSTRALIA
  2. Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, AUSTRALIA
  3. Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia

Aim:                      

Fluorodeoxyglucose Positron Emission Tomography (PET) scans are commonly used as part of the diagnosis, staging and management in lung cancer. Factors identify recurrence and survival after surgery include TNM stage, histological differentiation, lymphatic/vascular invasion and pleural invasion. Standard uptake value (SUV) has been shown to be a significant factor in predicting disease free survival.

We assessed if SUV is an independent factor for survival in resected non-small cell lung cancer.

 

Methods

Data from lung cancer patients with resected NSCLC was collected from a database from Fremantle Hospital. from 2004-2010. Information regarding histopathology, time of diagnosis and staging was abstracted from the database while data on recurrence and time of death was collected from patient notes or iSoft. Data was analysed using SPSS v 24. Binary logistic regression was used to assess effect of increased SUV max on recurrence or mortality.

 

Results

From 2004-2010, 109 patients underwent resection of their lung cancer. 8 patients had carcinoid and were excluded from the study. We were unable to assess SUV Max in 32 patients.

The median size of primary lesion was 30mm (IQR 26). 64.6% of cases were adenocarcinoma (n=42) with the remainder being SCC (32.3%, n=21) and large cell carcinoma (3.1%, n=2). The majority of cases were grade 2 (69.2%, n=45), and stage 1 (40%, n=26). 80% of patients received adjuvant treatment (n=52). At the end of study, 53.8% of patients had recurrent disease (n=35) and 61.5% of patients had died (n=40). There was no statistically significant effect of increased SUV max on recurrence (OR 1.06, 95% CI 0.97-1.15, p=0.209) or mortality (OR 1.05, 95% CI 0.96-1.14, p=0.317).

 

Conclusion

Our retrospective study did not show that SUV Max did not have any significant effect on recurrence or mortality. The statistical significance of our results was limited by small sample size.